RU2020113341A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2020113341A3 RU2020113341A3 RU2020113341A RU2020113341A RU2020113341A3 RU 2020113341 A3 RU2020113341 A3 RU 2020113341A3 RU 2020113341 A RU2020113341 A RU 2020113341A RU 2020113341 A RU2020113341 A RU 2020113341A RU 2020113341 A3 RU2020113341 A3 RU 2020113341A3
- Authority
- RU
- Russia
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/24—Apocynaceae (Dogbane family), e.g. plumeria or periwinkle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| USPCT/US2017/051553 | 2017-09-14 | ||
| PCT/US2017/051553 WO2018053123A1 (en) | 2016-09-14 | 2017-09-14 | Method and compositions for treating viral infection |
| US201862698365P | 2018-07-16 | 2018-07-16 | |
| PCT/US2018/042226 WO2019055119A1 (en) | 2017-09-14 | 2018-07-16 | Method and composition for treating viral infection |
| US62/698,365 | 2018-07-16 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2020113341A3 true RU2020113341A3 (en) | 2021-10-15 |
| RU2020113341A RU2020113341A (en) | 2021-10-15 |
Family
ID=65723839
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2020113341A RU2020113341A (en) | 2017-09-14 | 2018-07-16 | METHOD AND COMPOSITION FOR VIRAL INFECTION TREATMENT |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP3681508A4 (en) |
| JP (3) | JP6820450B2 (en) |
| KR (2) | KR102295179B1 (en) |
| AU (2) | AU2018334386B2 (en) |
| CA (1) | CA3075729A1 (en) |
| IL (2) | IL285232B (en) |
| MX (1) | MX2020002883A (en) |
| RU (1) | RU2020113341A (en) |
| WO (1) | WO2019055119A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202105728YA (en) * | 2020-03-31 | 2021-11-29 | Phoenix Biotechnology Inc | Method and compositions for treating coronavirus infection |
| US11806359B2 (en) | 2020-03-31 | 2023-11-07 | Phoenix Biotechnology, Inc. | Method and compositions for treating Coronavirus infection |
| ES2965161T3 (en) * | 2020-03-31 | 2024-04-11 | Phoenix Biotechnology Inc | Method and compositions for the treatment of coronavirus infection |
| EP4295854A3 (en) | 2020-03-31 | 2024-04-03 | Phoenix Biotechnology, Inc. | Method and compositions for treating coronavirus infection |
| FR3109297A1 (en) * | 2020-04-19 | 2021-10-22 | Ephyla | "New non-protein furin inhibitor" |
| WO2022094816A1 (en) * | 2020-11-04 | 2022-05-12 | Janssen Pharmaceuticals, Inc. | Solid formulation |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN165073B (en) | 1986-05-13 | 1989-08-12 | Ziya Ozel Huseyin | |
| US5236132A (en) | 1992-01-03 | 1993-08-17 | Vortec, Inc. | Gradient-force comminuter/dehydrator apparatus and method |
| US5598979A (en) | 1995-04-20 | 1997-02-04 | Vortec, Inc. | Closed loop gradient force comminuting and dehydrating system |
| CA2191923C (en) | 1996-12-03 | 2000-10-24 | Ji-Won Yoon | Portulaca oleracea and tumor cell growth |
| ATE522220T1 (en) | 1998-05-19 | 2011-09-15 | Res Dev Foundation | TRITERPONE COMPOSITIONS AND METHODS OF USE THEREOF |
| CA2354037A1 (en) | 1998-09-24 | 2000-03-30 | Ozelle Pharmaceuticals, Inc. | Extract of nerium species, pharmaceutical composition thereof and methods for preparation thereof |
| US6517015B2 (en) | 2000-03-21 | 2003-02-11 | Frank F. Rowley, Jr. | Two-stage comminuting and dehydrating system and method |
| CA2418479C (en) | 2000-08-18 | 2007-12-18 | The Board Of Trustees Of The University Of Illinois | Prodrugs of betulinic acid derivatives for the treatment of cancer |
| US9931316B2 (en) * | 2004-01-06 | 2018-04-03 | Paul Edward Stamets | Antiviral activity from medicinal mushrooms and their active constituents |
| US6715705B2 (en) | 2001-03-16 | 2004-04-06 | Frank F. Rowley, Jr. | Two-stage comminuting and dehydrating system and method |
| DE60204078T2 (en) | 2001-04-09 | 2006-01-26 | Loders Croklaan B.V. | Concentrate of triterpenes |
| CA2446748C (en) | 2001-05-11 | 2011-03-08 | University Of Ottawa | Anxiolytic marcgraviaceae compositions containing betulinic acid, betulinic acid derivatives, and methods |
| US20040082521A1 (en) | 2002-03-29 | 2004-04-29 | Azaya Therapeutics Inc. | Novel formulations of digitalis glycosides for treating cell-proliferative and other diseases |
| EP1513403B1 (en) * | 2002-05-28 | 2017-02-15 | Bette Pollard | Cardiac glycosides to treat cystic fibrosis and other il-8 dependent disorders |
| AU2003287526A1 (en) | 2002-11-06 | 2004-06-03 | Protein-stabilized liposomal formulations of pharmaceutical agents | |
| WO2004087121A2 (en) | 2003-03-28 | 2004-10-14 | Azaya Therapeutics, Inc. | Water soluble formulations of digitalis glycosides for treating cell-proliferative and other diseases |
| JP2007529544A (en) | 2004-03-17 | 2007-10-25 | パナコス ファーマシューティカルズ， インコーポレイテッド | Pharmaceutical salt of 3-O- (3 ', 3'-dimethylsuccinyl) betulinic acid |
| US7118508B2 (en) | 2004-07-28 | 2006-10-10 | General Motors Corporation | Planetary transmissions having three interconnected gear members and clutched input members |
| US8022055B2 (en) | 2005-02-09 | 2011-09-20 | Dabur Pharma Limited | Betulinic acid derivatives |
| WO2006105354A1 (en) | 2005-03-29 | 2006-10-05 | Regents Of The University Of Minnesota | Selective oxidation of triterpenes employing tempo |
| US20060252733A1 (en) | 2005-04-07 | 2006-11-09 | Novelix Pharmaceuticals, Inc. | Betulin, betulin derivatives, betulinic acid and betulinic acid derivatives as novel therapeutics in the treatment of disease of lipid and/or glucose metabolism |
| WO2006133314A2 (en) | 2005-06-08 | 2006-12-14 | Regents Of The University Of Minnesota | Synthesis of betulonic and betulinic aldehydes |
| WO2006132033A1 (en) | 2005-06-10 | 2006-12-14 | Pola Chemical Industries Inc. | Novel triterpenic acid derivative and preparation for external application for skin comprising the same |
| US7402325B2 (en) | 2005-07-28 | 2008-07-22 | Phoenix Biotechnology, Inc. | Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander |
| CN101374527A (en) | 2005-12-16 | 2009-02-25 | 帕纳克斯医药公司 | Preparation of pharmaceutical salts of 3-o-(3',3'-dimethylsuccinyl) betulinic acid |
| EP1803461A1 (en) * | 2005-12-27 | 2007-07-04 | Heinz-Herbert Fiebig | Therapeutic use of an extract from the leaves of Nerium oleander |
| GB0604535D0 (en) | 2006-03-07 | 2006-04-12 | Sndv Sprl | Betulonic acid derivatives |
| US20090203661A1 (en) | 2006-10-12 | 2009-08-13 | Safe Stephen H | Betulinic acid, derivatives and analogs thereof and uses therefor |
| TW200837074A (en) | 2006-11-03 | 2008-09-16 | Panacos Pharmaceuticals Inc | Extended triterpene derivatives |
| WO2008091532A1 (en) | 2007-01-19 | 2008-07-31 | Panacos Pharmaceuticals, Inc. | Salts of 3-o-(3',3'-dimethylsuccinyl)betulinic acid and solid state forms thereof |
| US8987212B2 (en) | 2007-08-07 | 2015-03-24 | Muhammed Majeed | Oleanoyl peptide composition and method of treating skin aging |
| KR101556805B1 (en) | 2007-11-13 | 2015-10-01 | 피닉스 바이오테크놀러지 인코포레이티드. | Method of determining the probability of a therapeutic response in cancer chemotherapy with cardiac glycoside |
| TWI453023B (en) | 2008-04-18 | 2014-09-21 | Reata Pharmaceuticals Inc | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17 |
| US8071632B2 (en) | 2008-04-18 | 2011-12-06 | Reata Pharmaceuticals, Inc. | Antioxidant inflammation modulators: novel derivatives of oleanolic acid |
| WO2009129545A1 (en) | 2008-04-18 | 2009-10-22 | Reata Pharmaceuticals, Inc. | Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the c-ring |
| ME02751B (en) | 2008-04-18 | 2018-01-20 | Reata Pharmaceuticals Inc | Antioxidant inflammation modulators: c-17 homologated oleanolic acid derivatives |
| CA2736568A1 (en) | 2008-09-10 | 2010-03-18 | Universite Du Quebec A Chicoutimi | Bidesmosidic betulin and betulinic acid derivatives and uses thereof as antitumor agents |
| WO2010053817A1 (en) | 2008-11-04 | 2010-05-14 | Trustees Of Dartmouth College | Betulinic acid derivatives and methods of use thereof |
| US8802727B2 (en) | 2009-07-14 | 2014-08-12 | Hetero Research Foundation, Hetero Drugs Limited | Pharmaceutically acceptable salts of betulinic acid derivatives |
| CN101704872B (en) | 2009-11-23 | 2012-06-27 | 张南 | 23-hydroxybetulinic acid derivatives as well as preparation methods and application thereof |
| US8685469B2 (en) | 2009-11-30 | 2014-04-01 | University Of Kwazulu-Natal | In vitro anti-sickling activity of betulinic acid, oleanolic acid and their derivatives |
| EP2523563B1 (en) | 2010-01-11 | 2017-06-21 | Phoenix Biotechnology Inc. | Method of treating neurological conditions with cardiac glycosides |
| US9011937B2 (en) | 2010-11-22 | 2015-04-21 | Phoenix Biotechnology, Inc. | Method of treating neurological conditions with extract of Nerium species or Thevetia species |
| TWI386415B (en) | 2010-02-02 | 2013-02-21 | Univ Kaohsiung Medical | Ursolic acid derivative and pharmaceutical composition thereof |
| TWI410431B (en) | 2010-12-22 | 2013-10-01 | Ind Tech Res Inst | Use of oleanolic acid derivatives in the manufacture of a medicament to prevent or treat hepatitis c |
| WO2012095705A1 (en) | 2011-01-10 | 2012-07-19 | Hetero Research Foundation | Pharmaceutically acceptable salts of novel betulinic acid derivatives |
| SI2670764T1 (en) | 2011-01-31 | 2016-03-31 | Bristol-Myers Squibb Company | C-28 amines of c-3 modified betulinic acid derivatives as hiv maturation inhibitors |
| CN102558280B (en) | 2011-11-18 | 2014-09-17 | 温州大学 | Method for producing 30-halogenated betulinic acid |
| NO2786757T3 (en) | 2011-12-01 | 2018-01-13 | ||
| US8987502B2 (en) | 2011-12-01 | 2015-03-24 | Hangzhou Bensheng Pharmaceutical Co., Ltd. | Oleanolic acid amidate derivatives, preparation methods and uses thereof |
| US20150119373A1 (en) | 2012-04-24 | 2015-04-30 | Hetero Research Foundation | Novel betulinic acid derivatives as hiv inhibitors |
| US8921419B2 (en) | 2012-05-08 | 2014-12-30 | Trustees Of Dartmouth College | Triterpenoids and compositions containing the same |
| US9120839B2 (en) | 2012-08-14 | 2015-09-01 | Nexoligo Co., Ltd. | Ursolic acid derivative and method for preparing same |
| US9278912B2 (en) | 2012-09-10 | 2016-03-08 | Reata Pharmaceuticals, Inc. | C13-hydroxy derivatives of oleanolic acid and methods of use thereof |
| JP6243428B2 (en) | 2012-09-10 | 2017-12-06 | リアタ ファーマシューティカルズ インコーポレイテッド | C17-alkanediyl and alkenediyl derivatives of oleanolic acid and methods of use thereof |
| CA2882417C (en) | 2012-09-10 | 2021-04-20 | Reata Pharmaceuticals, Inc. | C17-heteroaryl derivatives of oleanolic acid and methods of use thereof |
| WO2014105926A1 (en) | 2012-12-31 | 2014-07-03 | Hetero Research Foundation | Novel betulinic acid proline derivatives as hiv inhibitors |
| US9249180B2 (en) | 2013-02-25 | 2016-02-02 | Bristol-Myers Squibb Company | C-3 alkyl and alkenyl modified betulinic acid derivatives |
| US10011838B2 (en) * | 2014-02-12 | 2018-07-03 | Novozymes Ais | Yeast strain and microbial method for production of pentacyclic triterpenes and/or triterpenoids |
| WO2015195776A1 (en) | 2014-06-19 | 2015-12-23 | Bristol-Myers Squibb Company | Betulinic acid derivatives with hiv maturation inhibitory activity |
| US9492438B2 (en) * | 2014-07-25 | 2016-11-15 | Bette Pollard | Amphiphilic pyridinum compounds to treat epilepsy and other disorders of the nervous system |
| BR112017026294A2 (en) * | 2015-06-08 | 2018-09-18 | Dermarc LLC | topical pharmaceutical gel formulation, and method for treating or preventing a disease or condition. |
-
2018
- 2018-07-16 KR KR1020207007406A patent/KR102295179B1/en active IP Right Grant
- 2018-07-16 RU RU2020113341A patent/RU2020113341A/en unknown
- 2018-07-16 KR KR1020217026676A patent/KR20210107904A/en active IP Right Grant
- 2018-07-16 JP JP2020515911A patent/JP6820450B2/en active Active
- 2018-07-16 MX MX2020002883A patent/MX2020002883A/en unknown
- 2018-07-16 CA CA3075729A patent/CA3075729A1/en active Pending
- 2018-07-16 AU AU2018334386A patent/AU2018334386B2/en active Active
- 2018-07-16 IL IL285232A patent/IL285232B/en unknown
- 2018-07-16 EP EP18857189.7A patent/EP3681508A4/en active Pending
- 2018-07-16 WO PCT/US2018/042226 patent/WO2019055119A1/en unknown
-
2020
- 2020-03-09 IL IL273162A patent/IL273162B/en unknown
- 2020-06-25 AU AU2020204236A patent/AU2020204236B2/en active Active
-
2021
- 2021-01-04 JP JP2021000190A patent/JP7037673B2/en active Active
-
2022
- 2022-03-04 JP JP2022033642A patent/JP2022075755A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018334386B2 (en) | 2021-11-04 |
| JP6820450B2 (en) | 2021-01-27 |
| EP3681508A4 (en) | 2021-05-19 |
| IL285232B (en) | 2022-07-01 |
| JP2022075755A (en) | 2022-05-18 |
| IL285232A (en) | 2021-09-30 |
| AU2020204236B2 (en) | 2020-12-10 |
| EP3681508A1 (en) | 2020-07-22 |
| IL273162B (en) | 2021-08-31 |
| IL273162A (en) | 2020-04-30 |
| CA3075729A1 (en) | 2019-03-21 |
| AU2018334386A1 (en) | 2020-04-02 |
| MX2020002883A (en) | 2020-10-05 |
| KR102295179B1 (en) | 2021-08-30 |
| AU2020204236A1 (en) | 2020-07-16 |
| KR20210107904A (en) | 2021-09-01 |
| WO2019055119A1 (en) | 2019-03-21 |
| JP7037673B2 (en) | 2022-03-16 |
| JP2020534293A (en) | 2020-11-26 |
| JP2021063105A (en) | 2021-04-22 |
| RU2020113341A (en) | 2021-10-15 |
| KR20200081356A (en) | 2020-07-07 |